final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
Published 5 years ago • 576 plays • Length 2:45Download video MP4
Download video MP3
Similar videos
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
1:58
dr. rischin on keynote-048 results in head and neck squamous cell carcinoma
-
7:03
pembrolizumab for frontline head and neck cancer: keynote-048 results
-
7:56
keynote-048: progression post next line for r/m hnscc
-
7:03
lba8_pr - keynote-048: phase 3 study of first-line pembrolizumab in r/m hnscc
-
1:52
dr. burtness on promise of frontline pembrolizumab in metastatic hnscc
-
6:46
first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma
-
4:42
pembrolizumab for recurrent head and neck squamous cell carcinomas (hnscc)
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
-
5:48
the impact of systemic therapy and keynote-048 trial
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
5:05
pembrolizumab vs. standard treatment in patients with recurrent or metastatic head and neck cancer
-
3:55
checkpoint inhibitors for recurrent hnscc
-
1:56
eftilagimod alpha and pembrolizumab in patients with squamous head and neck carcinoma
-
2:37
pembrolizumab is effective in recurrent, metastatic squamous cell carcinomas of the head and neck
-
4:46
preliminary results from keynote-055: pembrolizumab in hnscc
-
19:28
asco/esmo 2020 - keynote 048 study update, what have we learned?
-
0:55
dr. cohen on immunotherapy in head and neck squamous cell carcinoma
-
5:00
keynote-055:pembrolizumab in hnscc